Bioventus Inc. (NASDAQ:BVS) Receives $16.25 Consensus Target Price from Brokerages

Bioventus Inc. (NASDAQ:BVS) has been given a consensus rating of “Buy” by the six analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.25.

A number of analysts recently weighed in on BVS shares. Barrington Research set a $18.00 price objective on shares of Bioventus in a research note on Thursday, August 6th. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 target price on shares of Bioventus in a research report on Tuesday, June 16th. Craig Hallum restated a “buy” rating and issued a $18.00 price target on shares of Bioventus in a report on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 6th.

Bioventus Trading Down 0.1%

BVS opened at $13.89 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. The stock’s fifty day moving average is $11.26 and its two-hundred day moving average is $9.87. The company has a market capitalization of $1.16 billion, a P/E ratio of 18.04, a PEG ratio of 1.77 and a beta of 0.63. Bioventus has a 52 week low of $6.26 and a 52 week high of $15.89.

Bioventus (NASDAQ:BVS) last issued its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.The business had revenue of $153.21 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Analysts forecast that Bioventus will post 0.79 earnings per share for the current year.

Institutional Trading of Bioventus

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Bioventus by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock valued at $1,486,000 after purchasing an additional 26,103 shares in the last quarter. Legal & General Group Plc boosted its position in Bioventus by 100.9% during the second quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock valued at $473,000 after purchasing an additional 35,873 shares in the last quarter. Rhumbline Advisers grew its stake in Bioventus by 20.6% in the second quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock valued at $431,000 after purchasing an additional 11,133 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in Bioventus by 32.5% in the second quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock valued at $1,401,000 after purchasing an additional 51,951 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.